The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.
Y. Omuro
No relevant relationships to disclose
T. Ikari
No relevant relationships to disclose
H. Ishii
Honoraria - Lilly
M. Ozaka
No relevant relationships to disclose
M. Suyama
No relevant relationships to disclose
Y. Matsumura
No relevant relationships to disclose
T. Itoi
No relevant relationships to disclose
N. Egawa
No relevant relationships to disclose
S. Yano
No relevant relationships to disclose
K. Hanada
No relevant relationships to disclose
Y. Kimura
No relevant relationships to disclose
T. Ukita
No relevant relationships to disclose
Y. Ishida
No relevant relationships to disclose
M. Tani
No relevant relationships to disclose
S. Ohoka
No relevant relationships to disclose
Y. Hirose
No relevant relationships to disclose
S. Hijioka
No relevant relationships to disclose
R. Watanabe
No relevant relationships to disclose
T. Ikeda
No relevant relationships to disclose
T. Nakajima
No relevant relationships to disclose